Exploratory secondary analysis of a phase 3 trial (4782 HER2-positive early breast cancers): adding pertuzumab favoured IDFS across ER/HER2 subgroups, most in FISH-low/ER-positive (HR 0.70, 0.51-0.95), least in FISH-high/ER-negative (HR 0.85, 0.59-1.25).
Secondary analysisn = 4,782
Agostinetto et al. The benefit of adjuvant pertuzumab and trastuzumab according to estrogen receptor and HER2 expression: a subanalysis of the APHINITY trial